A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

ABSTRACT: This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.

DISEASE(S): Carcinoma,Triple Negative Breast Neoplasms,Small Cell Lung Cancer,Fallopian Tube Cancer,Advanced Solid Tumors,Cervical Carcinoma,Squamous Cell Vulvar Carcinoma,Triple Negative Breast Cancer,Urothelial Carcinoma,Endometrial Neoplasms,Pancreatic Carcinoma,Lung Neoplasms,Gastric Or Gastroesophageal Junction Adenocarcinoma,Vulvar Neoplasms,Squamous Cell Penile Carcinoma,Colorectal Carcinoma,Fallopian Tube Neoplasms,Squamous Cell Carcinoma Of The Head And Neck,Gastric Cancer,Primary Peritoneal Carcinoma,Epithelial Ovarian Cancer,Colorectal Neoplasms,Carcinoma, Non-small-cell Lung,Ovarian Neoplasms,Renal Cell Carcinoma,Pancreatic Neoplasms,Non-small Cell Lung Carcinoma,Squamous Cell Anal Cancer,Cholangiocarcinoma,Hepatocellular Carcinoma,Nasopharyngeal Carcinoma,Intrahepatic Cholangiocarcinoma,Cervical Cancer,Melanoma,Small Cell Lung Carcinoma,Pancreatic Cancer,Anus Neoplasms,Carcinoma, Squamous Cell,Squamous Cell Carcinoma Of Head And Neck,Prostate Carcinoma,Non-small Cell Lung Cancer,Carcinoma, Ovarian Epithelial,Advanced Or Metastatic Solid Tumors,Prostate Cancer,Endometrial Carcinoma

PROVIDER: 2297842 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR